
22/04/2025
https://doi.org/10.1177/09760016251330369
The purpose of this study was to compare the clinical efficacy and safety of 3 mL (15 mg) of 0.5% hyperbaric bupivacaine and 3 mL (22.5 mg) of 0.75% hyperbaric ropivacaine for infraumbilical surgeries under spinal anaesthesia in terms of sensory and motor blockade onset and duration, as well as haemodynamic stability.
Methods:
This is a prospective randomised comparison study of 60 patients undergoing elective infraumbilical operations under SA at Apollo Main Hospital in Chennai. Based on inclusion and exclusion criteria, they were randomised into Group R, who received 3 mL of 0.75% hyperbaric ropivacaine (21 mg), and Group B, who received 3 mL of hyperbaric bupivacaine (15 mg).
Results:
Our study result shows that patients receiving 0.75% hyperbaric ropivacaine had sensory and motor block for a shorter amount of time than those receiving 0.5% hyperbaric bupivacaine. Patients who received 0.75% ropivacaine as opposed to 0.5% bupivacaine also experienced a delayed onset of motor as well as sensory block. The group receiving ropivacaine had a lower incidence of complications such as hypotension and fewer haemodynamic alterations than bupivacaine.
Conclusion:
This study concludes that ropivacaine is a suitable drug for spinal anaesthesia for procedures of intermediate duration since it has a quicker recovery profile than the widely used hyperbaric 0.5% bupivacaine. It is also equivalent in terms of block quality.
Sage India
Background and Aims: The purpose of this study was to compare the clinical efficacy and safety of 3 mL (15 mg) of 0.5% hyperbaric bupivacaine and 3 mL (22.5 mg)...